This inventor holds 2 USPTO granted patents and 2 published patent applications. Top assignee: Sumitomo Pharma Co., Ltd.. Active years: 2024-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2024-2025
Title: Shuya Yamada: Innovator in Medicinal Chemistry
Introduction
Shuya Yamada is a prominent inventor based in Osaka, Japan. He has made significant contributions to the field of medicinal chemistry, particularly in the development of novel compounds for treating central nervous system diseases. With a total of 2 patents to his name, Yamada's work is paving the way for new therapeutic options.
Latest Patents
Yamada's latest patents focus on nitrogen-containing saturated heterocyclyl derivatives. These inventions relate to medicaments designed to treat or prevent central nervous system diseases caused by abnormal protein aggregation in the brain. The active ingredients in these compounds are formulated to suppress or reduce the accumulation of these harmful proteins, showcasing Yamada's commitment to addressing critical health issues.
Career Highlights
Shuya Yamada is currently employed at Sumitomo Pharma Co., Ltd., where he continues to innovate in the pharmaceutical industry. His work is characterized by a strong emphasis on research and development, particularly in the area of neurodegenerative diseases. Yamada's contributions are recognized within the scientific community, and he is regarded as a leading figure in his field.
Collaborations
Yamada collaborates with esteemed colleagues, including Hitoshi Watanabe and Katsushi Kitahara. These partnerships enhance the research efforts at Sumitomo Pharma Co., Ltd. and contribute to the advancement of medicinal chemistry.
Conclusion
In summary, Shuya Yamada is a dedicated inventor whose work in medicinal chemistry is making a significant impact on the treatment of central nervous system diseases. His innovative patents and collaborations reflect his commitment to improving healthcare outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile